Gene-promoter hypermethylation as a biomarker in lung cancer
Top Cited Papers
- 1 September 2004
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 4 (9), 707-717
- https://doi.org/10.1038/nrc1432
Abstract
Silencing of genes by aberrant promoter hypermethylation is now recognized as a crucial component in cancer initiation and progression. Highly sensitive assays have been developed to assess gene-promoter methylation in biological fluids. The detection of methylated genes in sputum could lead to the development of a screening test to non-invasively identify early cancer in high-risk people.Keywords
This publication has 102 references indexed in Scilit:
- K-ras and p16INK4Aalterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokersLung Cancer, 2004
- Detecting lung cancer in plasma with the use of multiple genetic markersInternational Journal of Cancer, 2003
- The case for early detectionNature Reviews Cancer, 2003
- Lung Cancer Screening with CT: Mayo Clinic ExperienceRadiology, 2003
- Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancersOncogene, 2002
- Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survivalOncogene, 2001
- Chfr defines a mitotic stress checkpoint that delays entry into metaphaseNature, 2000
- Early Lung Cancer Action Project: overall design and findings from baseline screeningThe Lancet, 1999
- Selenium‐Dependent Peroxidases Suppress 5‐Lipoxygenase Activity in B‐Lymphocytes and Immature Myeloid CellsEuropean Journal of Biochemistry, 1996
- Changes in Bronchial Epithelium in Relation to Cigarette Smoking, 1955–1960 vs. 1970–1977New England Journal of Medicine, 1979